Recent research and development of PLGA/PLA microspheres/nanoparticles: A review in scientific and industrial aspects
Feng Qi1,2(), Jie Wu3, Hao Li2, Guanghui Ma3()
1. Beijing Nuokangda Pharmaceutical Technology Co., Ltd, Beijing 100176, China 2. Department of Mechanical and Aerospace Engineering, University of Missouri, MO 65211, USA 3. National Key Laboratory of Biochemical Engineering, Key Laboratory of Biopharmaceutical Production and Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
Poly(D,L-lactic-co-glycolic acid) (PLGA)/poly(lactic acid) (PLA) microspheres/nanoparticles are one of the most successful drug delivery systems (DDS) in lab and clinic. Because of good biocompatibility and biodegradability, they can be used in various areas, such as long-term release system, vaccine adjuvant, tissue engineering, etc. There have been 15 products available on the US market, but the system still has many problems during development and manufacturing, such as wide size distribution, drug stability issues, and so on. Recently, many new and modified methods have been developed to overcome the above problems. Some of the methods are easy to scale up, and have been available on the market to achieve pilot scale or even industrial production scale. Furthermore, the relevant FDA guidance on the DDS is still incomplete, especially for abbreviated new drug application. In this review, we present some recent achievement of the PLGA/PLA microspheres/nanoparticles, and discuss some promising manufacturing methods. Finally, we focus on the current FDA guidance on the DDS. The review provides an overview on the development of the system in pharmaceutical industry.
. [J]. Frontiers of Chemical Science and Engineering, 2019, 13(1): 14-27.
Feng Qi, Jie Wu, Hao Li, Guanghui Ma. Recent research and development of PLGA/PLA microspheres/nanoparticles: A review in scientific and industrial aspects. Front. Chem. Sci. Eng., 2019, 13(1): 14-27.
A JHarvey, S A Kaestner, D E Sutter, N G Harvey, J A Mikszta, R J Pettis. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharmaceutical Research, 2011, 28(1): 107–116 https://doi.org/10.1007/s11095-010-0123-9
HOkada. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Advanced Drug Delivery Reviews, 1997, 28(1): 43–70 https://doi.org/10.1016/S0169-409X(97)00050-1
4
F YHan, K J Thurecht, A K Whittaker, M T Smith. Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Frontiers in Pharmacology, 2016, 7: 185 https://doi.org/10.3389/fphar.2016.00185
5
M AWashington, D JSwiner, K RBell, M VFedorchak, S RLittle, T YMeyer. The impact of monomer sequence and stereochemistry on the swelling and erosion of biodegradable poly(lactic-co-glycolic acid) matrices. Biomaterials, 2017, 117: 66–76 https://doi.org/10.1016/j.biomaterials.2016.11.037
6
ITomic, A Vidis-Millward, MMueller-Zsigmondy, J MCardot. Setting accelerated dissolution test for PLGA microspheres containing peptide, investigation of critical parameters affecting drug release rate and mechanism. International Journal of Pharmaceutics, 2016, 505(1-2): 42–51 https://doi.org/10.1016/j.ijpharm.2016.03.048
7
G ZZhu, S P Schwendeman. Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: Mechanism of stabilization by basic additives. Pharmaceutical Research, 2000, 17(3): 351–357 https://doi.org/10.1023/A:1007513425337
8
H HKwak, W S Shim, M K Choi, M K Son, Y J Kim, H C Yang, T H Kim, G I Lee, B M Kim, S H Kang, et al. Development of a sustained-release recombinant human growth hormone formulation. Journal of Controlled Release, 2009, 137(2): 160–165 https://doi.org/10.1016/j.jconrel.2009.03.014
9
B SKim, J M Oh, H Hyun, K SKim, S HLee, Y HKim, KPark, H B Lee, M S Kim. Insulin-loaded microcapsules for in vivo delivery. Molecular Pharmaceutics, 2009, 6(2): 353–365 https://doi.org/10.1021/mp800087t
10
H HKwak, W S Shim, S Hwang, M KSon, Y JKim, T HKim, Z HYoon, H JYoun, G ILee, S HKang, et al. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharmaceutical Research, 2009, 26(11): 2504–2512 https://doi.org/10.1007/s11095-009-9966-3
11
M CGaspar, N Gregoire, J J SSousa, A A C CPais, ILamarche, PGobin, J COlivier, SMarchand, WCouet. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. European Journal of Pharmaceutical Sciences, 2016, 93: 184–191 https://doi.org/10.1016/j.ejps.2016.08.024
12
T SFeng, H Y Tian, C N Xu, L Lin, Z GXie, M H WLam, H JLiang, X SChen. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88(3): 1086–1093 https://doi.org/10.1016/j.ejpb.2014.09.012
13
A HSalama, A A Mahmoud, R Kamel. A novel method for preparing surface-modified fluocinolone acetonide loaded PLGA nanoparticles for ocular use: In vitro and in vivo evaluations. AAPS PharmSciTech, 2016, 17(5): 1159–1172 https://doi.org/10.1208/s12249-015-0448-0
14
FQi, J Wu, Q ZFan, FHe, G F Tian, T Y Yang, G H Ma, Z G Su. Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability. Colloids and Surfaces. B, Biointerfaces, 2013, 112: 492–498 https://doi.org/10.1016/j.colsurfb.2013.08.048
15
TParumasivam, S S Y Leung, D H Quan, J A Triccas, W J Britton, H K Chan. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. European Journal of Pharmaceutical Sciences, 2016, 88: 1–11 https://doi.org/10.1016/j.ejps.2016.03.024
16
S DNath, S Son, ASadiasa, Y KMin, B TLee. Preparation and characterization of PLGA microspheres by the electrospraying method for delivering simvastatin for bone regeneration. International Journal of Pharmaceutics, 2013, 443(1-2): 87–94 https://doi.org/10.1016/j.ijpharm.2012.12.037
17
V GWong, M W L Hu. US Patent 6726918 B1, 2004-04-27
18
D GCallanan, S Gupta, D SBoyer, T ACiulla, M ASinger, B DKuppermann, C CLiu, X YLi, D AHollander, R MSchiffman, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology, 2013, 120(9): 1843–1851 https://doi.org/10.1016/j.ophtha.2013.02.018
19
J RVillanueva, IBravo-Osuna, RHerrero-Vanrell, I T MMartinez, M GNavarro. Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration. European Journal of Pharmaceutical Sciences, 2016, 92: 287–297 https://doi.org/10.1016/j.ejps.2016.03.012
20
WZhang, L Wang, YLiu, XChen, Q Liu, JJia, TYang, S Qiu, GMa. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials, 2014, 35(23): 6086–6097 https://doi.org/10.1016/j.biomaterials.2014.04.022
21
W FZhang, L Y Wang, T Y Yang, Y Liu, X MChen, QLiu, J L Jia, G H Ma. Immunopotentiator-loaded polymeric microparticles as robust adjuvant to improve vaccine efficacy. Pharmaceutical Research, 2015, 32(9): 2837–2850 https://doi.org/10.1007/s11095-015-1666-6
22
SHidaka. Conflicting effects by antibodies against connexin36 during the action of intracellular Cyclic-AMP onto electrical synapses of retinal ganglion cells. Journal of Integrative Neuroscience, 2016, 15(4): 571–591 https://doi.org/10.1142/S021963521650031X
23
VPavot, M Berthet, JResseguier, SLegaz, NHandke, S CGilbert, SPaul, B Verrier. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. Nanomedicine (London), 2014, 9(17): 2703–2718 https://doi.org/10.2217/nnm.14.156
24
QLiu, X Chen, JJia, WZhang, TYang, L Wang, GMa. pH-responsive poly(D,L-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote immune response. ACS Nano, 2015, 9(5): 4925–4938 https://doi.org/10.1021/nn5066793
25
PGentile, V Chiono, ICarmagnola, P VHatton. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. International Journal of Molecular Sciences, 2014, 15(3): 3640–3659 https://doi.org/10.3390/ijms15033640
26
BDhandayuthapani, Y Yoshida, TMaekawa, D SKumar. Polymeric scaffolds in tissue engineering application: A review. International Journal of Polymer Science, 2011, 2011
27
QWang, Z Gu, SJamal, M SDetamore, CBerkland. Hybrid hydroxyapatite nanoparticle colloidal gels are injectable fillers for bone tissue engineering. Tissue Engineering. Part A, 2013, 19(23-24): 2586–2593 https://doi.org/10.1089/ten.tea.2013.0075
28
XWang, X Wu, H LXing, G LZhang, QShi, L E, NLiu, TYang, D Wang, FQi, LWang, H Liu. Porous nanohydroxyapatite/collagen scaffolds loading insulin PLGA particles for restoration of critical size bone defect. ACS Applied Materials & Interfaces, 2017, 9(13): 11380–11391 https://doi.org/10.1021/acsami.6b13566
29
A EReszko, N S Sadick, C M Magro, J Farber. Late-onset subcutaneous nodules after poly-L-lactic acid injection. Dermatologic Surgery, 2009, 35(1): 380–384 https://doi.org/10.1111/j.1524-4725.2008.01042.x
30
M AValantin, C Aubron-Olivier, JGhosn, ELaglenne, MPauchard, HSchoen, RBousquet, PKatz, D Costagliola, CKatlama. Polylactic acid implants (New-Fill)((R)) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS (London, England), 2003, 17(17): 2471–2477 https://doi.org/10.1097/00002030-200311210-00009
31
G JMoyle, L Lysakova, SBrown, NSibtain, JHealy, CPriest, SMandalia, S EBarton. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Medicine, 2004, 5(2): 82–87 https://doi.org/10.1111/j.1468-1293.2004.00190.x
32
S MLam, B Azizzadeh, MGraivier. Injectable poly-L-lactic acid (Sculptra): Technical considerations in soft-tissue contouring. Plastic and Reconstructive Surgery, 2006, 118(3 Suppl): 55s–63s https://doi.org/10.1097/01.prs.0000234612.20611.5a
33
SGhosh, S Sahu, LAgrawal, TShiga, ABandyopadhyay. Inventing a co-axial atomic resolution patch clamp to study a single resonating protein complex and ultra-low power communication deep inside a living neuron cell. Journal of Integrative Neuroscience, 2016, 15(4): 403–433 https://doi.org/10.1142/S0219635216500321
34
SGogolewski, M Jovanovic, S MPerren, J GDillon, M KHughes. Tissue-response and in-vivo degradation of selected polyhydroxyacids-polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). Journal of Biomedical Materials Research, 1993, 27(9): 1135–1148 https://doi.org/10.1002/jbm.820270904
35
YYang, N Bajaj, PXu, KOhn, M D Tsifansky, Y Yeo. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials, 2009, 30(10): 1947–1953 https://doi.org/10.1016/j.biomaterials.2008.12.044
36
T ZZhang, Q Y Zhang, J S Chen, K Fang, JDou, NGu. The controllable preparation of porous PLGA microspheres by the oil/water emulsion method and its application in 3D culture of ovarian cancer cells. Colloids and Surfaces A-Physicochemical and Engineering Aspects, 2014, 452: 115–124
37
FQi, J Wu, G QSun, F FNan, TNgai, G H Ma. Systematic studies of Pickering emulsions stabilized by uniform-sized PLGA particles: Preparation and stabilization mechanism. Journal of Materials Chemistry. B, Materials for Biology and Medicine, 2014, 2(43): 7605–7611 https://doi.org/10.1039/C4TB01165A
38
YXia, J Wu, WWei, YDu, T Wan, XMa, WAn, A Guo, CMiao, HYue, et al. Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination. Nature Materials, 2018, 17(2): 187–194 https://doi.org/10.1038/nmat5057
39
FNan, J Wu, FQi, YLiu, T Ngai, GMa. Uniform chitosan-coated alginate particles as emulsifiers for preparation of stable Pickering emulsions with stimulus dependence. Colloids and Surfaces. A, Physicochemical and Engineering Aspects, 2014, 456: 246–252 https://doi.org/10.1016/j.colsurfa.2014.05.017
40
FQi, J Wu, T YYang, G HMa, Z GSu. Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification. Acta Biomaterialia, 2014, 10(10): 4247–4256 https://doi.org/10.1016/j.actbio.2014.06.018
41
ARawat, E Stippler, V PShah, D JBurgess. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. International Journal of Pharmaceutics, 2011, 420(2): 198–205 https://doi.org/10.1016/j.ijpharm.2011.08.035
MZhang, Y Ma, RLi, JZeng, Z Li, YTang, DSun. RhBMP-2-loaded Poly(lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for protein delivery. Journal of Biomaterials Science. Polymer Edition, 2017, 28(18): 2205–2219 https://doi.org/10.1080/09205063.2017.1390381
44
GDella Porta, RCampardelli, VCricchio, FOliva, NMaffulli, EReverchon. Injectable PLGA/hydroxyapatite/chitosan microcapsules produced by supercritical emulsion extraction technology: An in vitro study on teriparatide/gentamicin controlled release. Journal of Pharmaceutical Sciences, 2016, 105(7): 2164–2172 https://doi.org/10.1016/j.xphs.2016.05.002
45
NFalco, E Reverchon, GDella Porta. Injectable PLGA/hydrocortisone formulation produced by continuous supercritical emulsion extraction. International Journal of Pharmaceutics, 2013, 441(1-2): 589–597 https://doi.org/10.1016/j.ijpharm.2012.10.039
46
GDella Porta, RCampardelli, EReverchon. Monodisperse biopolymer nanoparticles by continuous supercritical emulsion extraction. Journal of Supercritical Fluids, 2013, 76: 67–73 https://doi.org/10.1016/j.supflu.2013.01.009
47
RCampardelli, G Della Porta, VGomez, SIrusta, EReverchon, JSantamaria. Encapsulation of titanium dioxide nanoparticles in PLA microspheres using supercritical emulsion extraction to produce bactericidal nanocomposites. Journal of Nanoparticle Research, 2013, 15(10): 1987–1997 https://doi.org/10.1007/s11051-013-1987-5
48
GDella Porta, NFalco, EGiordano, EReverchon. PLGA microspheres by supercritical emulsion extraction: A study on insulin release in myoblast culture. Journal of Biomaterials Science. Polymer Edition, 2013, 24(16): 1831–1847 https://doi.org/10.1080/09205063.2013.807457
49
GDella Porta, B NNguyen, RCampardelli, EReverchon, J PFisher. Synergistic effect of sustained release of growth factors and dynamic culture on osteoblastic differentiation of mesenchymal stem cells. Journal of Biomedical Materials Research. Part A, 2015, 103(6): 2161–2171 https://doi.org/10.1002/jbm.a.35354
50
RCampardelli, G Della Porta, LGomez, SIrusta, EReverchon, JSantamaria. Au-PLA nanocomposites for photothermally controlled drug delivery. Journal of Materials Chemistry. B, Materials for Biology and Medicine, 2014, 2(4): 409–417 https://doi.org/10.1039/C3TB21099E
51
W LJiang, S P Schwendeman. Stabilization of tetanus toxoid encapsulated in PLGA microspheres. Molecular Pharmaceutics, 2008, 5(5): 808–817 https://doi.org/10.1021/mp800027f
52
Z QLiu, X Li, B SXiu, C MDuan, J XLi, X HZhang, X QYang, W HDai, HJohnson, H QZhang, et al. A novel and simple preparative method for uniform-sized PLGA microspheres: Preliminary application in antitubercular drug delivery. Colloids and Surfaces. B, Biointerfaces, 2016, 145: 679–687 https://doi.org/10.1016/j.colsurfb.2016.05.085
53
L HHung, S Y Teh, J Jester, A PLee. PLGA micro/nanosphere synthesis by droplet microfluidic solvent evaporation and extraction approaches. Lab on a Chip, 2010, 10(14): 1820–1825 https://doi.org/10.1039/c002866e
54
YWei, Y X Wang, L Y Wang, D X Hao, G H Ma. Fabrication strategy for amphiphilic microcapsules with narrow size distribution by premix membrane emulsification. Colloids and Surfaces. B, Biointerfaces, 2011, 87(2): 399–408 https://doi.org/10.1016/j.colsurfb.2011.05.051
55
M MCrowley, F Zhang, M ARepka, SThumma, S BUpadhye, S KBattu, J WMcGinity, CMartin. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Development and Industrial Pharmacy, 2007, 33(9): 909–926 https://doi.org/10.1080/03639040701498759
56
YGuo, Y Yang, LHe, RSun, C Pu, BXie, HHe, Y Zhang, TYin, YWang, X Tang. Injectable sustained-release depots of PLGA microspheres for insoluble drugs prepared by hot-melt extrusion. Pharmaceutical Research, 2017, 34(10): 2211–2222 https://doi.org/10.1007/s11095-017-2228-x
57
S JBakri, A F Omar. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. Journal of Ocular Pharmacology and Therapeutics, 2012, 28(5): 547–549 https://doi.org/10.1089/jop.2011.0184
58
TTice. US Patent 2012/0156304 A1, 2012-06-21
59
EZeigerson. US Patent 8916196 B2, 2014-12-23
60
G HMa. Microencapsulation of protein drugs for drug delivery: Strategy, preparation, and applications. Journal of Controlled Release, 2014, 193: 324–340 https://doi.org/10.1016/j.jconrel.2014.09.003
61
FQi, L Q Yang, J Wu, G HMa, Z GSu. Microcosmic mechanism of dication for inhibiting acylation of acidic peptide. Pharmaceutical Research, 2015, 32(7): 2310–2317 https://doi.org/10.1007/s11095-015-1622-5
62
RLiu, G H Ma, F T Meng, Z G Su. Preparation of uniform-sized PLA microcapsules by combining Shirasu Porous Glass membrane emulsification technique and multiple emulsion-solvent evaporation method. Journal of Controlled Release, 2005, 103(1): 31–43 https://doi.org/10.1016/j.jconrel.2004.11.025
63
RLiu, G H Ma, Y H Wan, Z G Su. Influence of process parameters on the size distribution of PLA microcapsules prepared by combining membrane emulsification technique and double emulsion-solvent evaporation method. Colloids and Surfaces. B, Biointerfaces, 2005, 45(3-4): 144–153 https://doi.org/10.1016/j.colsurfb.2005.08.004
64
RLiu, S S Huang, Y H Wan, G H Ma, Z G Su. Preparation of insulin-loaded PLA/PLGA microcapsules by a novel membrane emulsification method and its release in vitro. Colloids and Surfaces. B, Biointerfaces, 2006, 51(1): 30–38 https://doi.org/10.1016/j.colsurfb.2006.05.014
65
D MLloyd, I T Norton, F Spyropoulos. Processing effects during rotating membrane emulsification. Journal of Membrane Science, 2014, 466: 8–17 https://doi.org/10.1016/j.memsci.2014.04.035
66
Y JLiang, H Yu, GFeng, LZhuang, WXi, M Ma, JChen, NGu, Y Zhang. High-performance poly(lactic-co-glycolic acid)-magnetic microspheres prepared by rotating membrane emulsification for transcatheter arterial embolization and magnetic ablation in VX2 liver tumors. ACS Applied Materials & Interfaces, 2017, 9(50): 43478–43489 https://doi.org/10.1021/acsami.7b14330
67
VGupta, Y Khan, C JBerkland, C TLaurencin, M SDetamore. Microsphere-based scaffolds in regenerative engineering. Annual Review of Biomedical Engineering, 2017, 19(1): 135–161 https://doi.org/10.1146/annurev-bioeng-071516-044712
68
CBerkland, K K Kim, D W Pack. Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. Journal of Controlled Release, 2001, 73(1): 59–74 https://doi.org/10.1016/S0168-3659(01)00289-9
69
MYe, S Kim, KPark. Issues in long-term protein delivery using biodegradable microparticles. Journal of Controlled Release, 2010, 146(2): 241–260 https://doi.org/10.1016/j.jconrel.2010.05.011
70
RKumar, M J Palmieri Jr. Points to consider when establishing drug product specifications for parenteral microspheres. AAPS Journal, 2010, 12(1): 27–32 https://doi.org/10.1208/s12248-009-9156-6
JWong, A Brugger, AKhare, MChaubal, PPapadopoulos, BRabinow, JKipp, J Ning. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Advanced Drug Delivery Reviews, 2008, 60(8): 939–954 https://doi.org/10.1016/j.addr.2007.11.008
73
YWei, Y X Wang, W Wang, S VHo, FQi, G H Ma, Z G Su. Microcosmic mechanisms for protein incomplete release and stability of various amphiphilic mPEG-PLA microspheres. Langmuir, 2012, 28(39): 13984–13992 https://doi.org/10.1021/la3017112
74
MMorlock, H Koll, GWinter, TKissel. Microencapsulation of Rh-erythropoietin, using biodegradable poly(D,L-lactide-co-glycolide): Protein stability and the effects of stabilizing excipients. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 43(1): 29–36 https://doi.org/10.1016/S0939-6411(96)00017-3
75
J LCleland, E T Duenas, A Park, ADaugherty, JKahn, J Kowalski, ACuthbertson. Development of poly-(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. Journal of Controlled Release, 2001, 72(1-3): 13–24 https://doi.org/10.1016/S0168-3659(01)00258-9
76
LMeinel, O E Illi, J Zapf, MMalfanti, H PMerkle, BGander. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. Journal of Controlled Release, 2001, 70(1-2): 193–202 https://doi.org/10.1016/S0168-3659(00)00352-7
77
JKang, F Wu, Y PCai, M XXu, MHe, W E Yuan. Development of recombinant human growth hormone (RhGH) sustained-release microspheres by a low temperature aqueous phase/aqueous phase emulsion method. European Journal of Pharmaceutical Sciences, 2014, 62: 141–147 https://doi.org/10.1016/j.ejps.2014.05.027
78
X YHong, L M Wei, L Q Ma, Y H Chen, Z G Liu, W Yuan. Novel preparation method for sustained-release PLGA microspheres using water-in-oil-in-hydrophilic-oil-in-water emulsion. International Journal of Nanomedicine, 2013, 8: 2433–2441
79
MSandor, A Riechel, IKaplan, EMathiowitz. Effect of lecithin and MgCO3 as additives on the enzymatic activity of carbonic anhydrase encapsulated in poly(lactide-co-glycolide) (PLGA) microspheres. Biochimica Et Biophysica Acta-General Subjects, 2002, 1570(1): 63–74 https://doi.org/10.1016/S0304-4165(02)00153-8
S PSchwendeman, A MSophocleous, YZhang. A new class of inhibitors of peptide sorption and acylation in PLGA. Journal of Controlled Release, 2009, 137(3-4): 179–184
83
M MPakulska, I E Donaghue, J M Obermeyer, A Tuladhar, C KMcLaughlin, T NShendruk, M SShoichet. Encapsulation-free controlled release: Electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles. Science Advances, 2016, 2(5): e1600519–e1600519 https://doi.org/10.1126/sciadv.1600519
84
ARawat, D J Burgess. USP apparatus 4 method for in vitro release testing of protein loaded microspheres. International Journal of Pharmaceutics, 2011, 409(1-2): 178–184 https://doi.org/10.1016/j.ijpharm.2011.02.057
85
J VAndhariya, D JBurgess. Recent advances in testing of microsphere drug delivery systems. Expert Opinion on Drug Delivery, 2016, 13(4): 593–608 https://doi.org/10.1517/17425247.2016.1134484
86
B SZolnik, P E Leary, D J Burgess. Elevated temperature accelerated release testing of PLGA microspheres. Journal of Controlled Release, 2006, 112(3): 293–300 https://doi.org/10.1016/j.jconrel.2006.02.015
87
ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1a (R2). 2003
88
NZheng, D J D Sun, P Zou, W LJiang. Scientific and regulatory considerations for generic complex drug products containing nanomaterials. AAPS Journal, 2017, 19(3): 619–631 https://doi.org/10.1208/s12248-017-0044-1
